Get the Stockscreener App
2.425
15.66%
0.345
Acumen Pharmaceuticals Inc stock is traded at $2.425, with a volume of 2.83M.
It is up +15.66% in the last 24 hours and up +14.02% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$2.08
Open:
$2.24
24h Volume:
2.83M
Relative Volume:
6.65
Market Cap:
$146.59M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-2.1652
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
+29.34%
1M Performance:
+14.02%
6M Performance:
+53.24%
1Y Performance:
+48.51%
1-Day Range:
$2.23
$2.64
1-Week Range:
$1.76
$3.01
52-Week Range:
$0.8551
$3.01
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.42 | 125.99M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.12 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
869.32 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
361.98 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.19 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $7.00 at BTIG Research - MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Acumen Pharmaceuticals’ Share Volatility: Insight Into Recent Developments - StocksToTrade
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS? - Yahoo Finance
Acumen Pharma CFO Zuga sells shares worth $7.6k By Investing.com - Investing.com Canada
Acumen Pharmaceuticals CLO sells shares worth $16,720 By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals CEO sells shares worth $21993 By Investing.com - Investing.com India
Acumen Pharma CMO Siemers sells $5.8k in ABOS stock By Investing.com - Investing.com Canada
Acumen Pharmaceuticals CEO sells shares worth $21993 - Investing.com
Daniel Joseph Oconnell Sells 9,346 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock - MarketBeat
Acumen Pharmaceuticals CLO sells shares worth $16,720 - Investing.com
"Study Within A Study" Reveals Best Recruitment Strategies For Alzheimer's Trials - Clinical Leader
VIX Spike: How does Acumen Pharmaceuticals Inc perform in inflationary periods2025 Technical Overview & Smart Swing Trading Techniques - baoquankhu1.vn
EV Market: What is the earnings history of Acumen Pharmaceuticals IncQuarterly Performance Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Acumen Pharmaceuticals Inc. (ABOS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Daniel Joseph Oconnell Sells 12,941 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock - Defense World
Acumen Pharma COO Barton sells $6.5k in shares By Investing.com - Investing.com UK
Meisner, Acumen Pharmaceuticals CLO, sells $91k in ABOS stock By Investing.com - Investing.com Nigeria
Acumen Pharma CEO O’Connell sells $47k in shares By Investing.com - Investing.com Canada
Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,941 Shares - MarketBeat
Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Sells $14,820.26 in Stock - MarketBeat
Insider Selling: Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Sells 6,888 Shares of Stock - MarketBeat
Meisner, Acumen Pharmaceuticals CLO, sells $91k in ABOS stock - Investing.com
Acumen Pharmaceuticals, Inc Updates Corporate Presentation with New Data - TradingView
Acumen Pharmaceuticals (NASDAQ:ABOS) Insider Sells $11,769.94 in Stock - Defense World
Acumen Pharmaceuticals COO Barton Russell sells shares worth $4,692 - MSN
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Acumen Pharmaceuticals CFO sells shares totaling $56,619 - MSN
Acumen Pharma president Doherty sells $15k in ABOS stock - Investing.com
Acumen pharma chief regulatory officer sells $2k in shares By Investing.com - Investing.com South Africa
Acumen pharma chief regulatory officer sells $2k in shares - Investing.com
Acumen Pharma president Doherty sells $15k in ABOS stock By Investing.com - Investing.com UK
James Doherty Sells 6,467 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock - MarketBeat
Will Acumen Pharmaceuticals Inc. stock outperform international peers2025 Trading Volume Trends & Breakout Confirmation Alerts - ulpravda.ru
Can Acumen Pharmaceuticals Inc. stock beat market expectations this quarterQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - ulpravda.ru
Will Acumen Pharmaceuticals Inc. stock outperform value stocks2025 Pullback Review & Fast Entry Momentum Alerts - Улправда
Can Acumen Pharmaceuticals Inc. stock maintain growth trajectoryMarket Volume Report & Smart Allocation Stock Tips - ulpravda.ru
Acumen Pharmaceuticals CLO sells $52,689 in shares By Investing.com - Investing.com UK
Eric Siemers Sells 6,834 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock - MarketBeat
Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Matt Zuga Sells 5,100 Shares - MarketBeat
Acumen Pharma CMO Siemers sells $21k in ABOS stock By Investing.com - Investing.com Canada
Acumen Pharmaceuticals CLO sells $52,689 in shares - Investing.com
Acumen Pharma CEO O’Connell sells $94k in shares By Investing.com - Investing.com Canada
Acumen Pharma CFO Zuga sells $29k in ABOS stock By Investing.com - Investing.com Canada
Acumen Pharmaceuticals, Inc.Common Stock (NQ: ABOS - FinancialContent
Is Acumen Pharmaceuticals Inc. stock supported by innovation pipelineRisk-Reward Ratio Analysis & Fast Profit Portfolio Plans - Улправда
Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 37,755 Shares - MarketBeat
Los Angeles Daily NewsAcumen Pharmaceuticals, Inc.Common Stock (Nasdaq:ABOS) Detailed Stock Data - FinancialContent
Acumen Pharmaceuticals chief legal officer sells shares worth $5,434 - MSN
Need help Profitable sectors business with absence of listed companiesPrice Channel Trading & Free Real-Time Trading Alerts Every Day - bollywoodhelpline.com
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 23 '26 |
Sale |
1.90 |
5,633 |
10,718 |
173,999 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '26 |
Sale |
1.81 |
2,247 |
4,063 |
180,686 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 22 '26 |
Sale |
1.84 |
1,054 |
1,939 |
179,632 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '26 |
Sale |
1.80 |
2,331 |
4,204 |
256,266 |
| Siemers Eric | Chief Medical Officer |
Jan 22 '26 |
Sale |
1.82 |
895 |
1,629 |
255,371 |
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '26 |
Sale |
1.81 |
2,473 |
4,469 |
306,611 |
| Zuga Matt | CFO & Chief Business Officer |
Jan 22 '26 |
Sale |
1.86 |
1,687 |
3,138 |
304,924 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '26 |
Sale |
1.81 |
9,346 |
16,927 |
883,964 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 22 '26 |
Sale |
1.88 |
2,689 |
5,066 |
881,275 |
| Barton Russell | Chief Operating Officer |
Jan 21 '26 |
Sale |
1.81 |
2,315 |
4,181 |
205,554 |
2.34%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):